Does Rallies show 13F holders for ZYME?

Yes. Rallies tracks hedge fund and 13F ownership data for ZYME, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ZYME research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ZYME. It does not provide personalized investment advice.

ZYME (Zymeworks Inc.) Stock Analysis - Hedge Fund Holdings

Zymeworks Inc. (ZYME) is a publicly traded Healthcare sector company. As of May 20, 2026, ZYME trades at $24.98 with a market cap of $1.80B and a P/E ratio of -6.10. ZYME moved +1.86% today. Year to date, ZYME is -2.51%; over the trailing twelve months it is +99.84%. Its 52-week range spans $9.03 to $29.75. Analyst consensus is strong buy with an average price target of $39.89. Rallies surfaces ZYME's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ZYME stock?

Hedge funds tracked by Rallies that own ZYME include Redmile Group and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Zymeworks Inc..

ZYME Key Metrics

Key financial metrics for ZYME
Metric	Value
Price	$24.98
Market Cap	$1.80B
P/E Ratio	-6.10
EPS	$-4.08
Dividend Yield	0.00%
52-Week High	$29.75
52-Week Low	$9.03
Volume	429.52K
Avg Volume	0
Revenue (TTM)	$31.62M
Net Income	$-236.97M
Gross Margin	0.00%

Top Hedge Funds Holding ZYME

Redmile Group holds 491.65K shares of ZYME, changed +0.00% as of Mar 31, 2026.
Panagora Asset holds 206.85K shares of ZYME, changed +164.06% as of Mar 31, 2026.

Latest ZYME News

Zymeworks ZW191 Achieves 61% ORR and 7.6-Month PFS in Phase 1 — Apr 21, 2026
Zymeworks Showcases Six ADC Programs Including Pan-RAS Inhibitors with 1 mg/kg Efficacy — Apr 17, 2026
Zymeworks Appoints Schayowitz EVP R&D and Platshon EVP Business Officer — Apr 9, 2026
Zymeworks Appoints Former Royalty Pharma SVP Kristin Stafford as CFO — Apr 1, 2026
Zymeworks Scores FDA Fast Track for FRα-Targeting ZW191 in Ovarian Cancer — Mar 30, 2026

Recent ZYME Insider Trades

Hollywood Mark sold 6.12K (~$138.76K) on Jan 12, 2026.
Smith Jeffrey T L sold 9.31K (~$211.09K) on Jan 12, 2026.
Moore Paul Andrew sold 9.56K (~$216.76K) on Jan 12, 2026.

ZYME Analyst Consensus

11 analysts cover ZYME: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.89.

Common questions about ZYME

Who owns ZYME stock?: Hedge funds tracked by Rallies that own ZYME include Redmile Group and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Zymeworks Inc..
Does Rallies show 13F holders for ZYME?: Yes. Rallies tracks hedge fund and 13F ownership data for ZYME, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ZYME research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ZYME. It does not provide personalized investment advice.